WO2015183963A3 - Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations - Google Patents

Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations Download PDF

Info

Publication number
WO2015183963A3
WO2015183963A3 PCT/US2015/032689 US2015032689W WO2015183963A3 WO 2015183963 A3 WO2015183963 A3 WO 2015183963A3 US 2015032689 W US2015032689 W US 2015032689W WO 2015183963 A3 WO2015183963 A3 WO 2015183963A3
Authority
WO
WIPO (PCT)
Prior art keywords
phe
active
parabenzoquinones
lys
arg
Prior art date
Application number
PCT/US2015/032689
Other languages
English (en)
Other versions
WO2015183963A2 (fr
Inventor
D. Travis Wilson
Mark BAMBERGER
Peter OATES
Original Assignee
Stealth Peptides International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International, Inc. filed Critical Stealth Peptides International, Inc.
Publication of WO2015183963A2 publication Critical patent/WO2015183963A2/fr
Publication of WO2015183963A3 publication Critical patent/WO2015183963A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés et des compositions de traitement et/ou de prévention de maladies ou d'états pathologiques consistant à administrer des parabenzoquinones à activité redox (RPBQ), et/ou des dérivés ou des analogues de ceux-ci d'origine naturelle ou artificielle, ou des sels de ceux-ci pharmaceutiquement acceptables, seuls ou en combinaison avec un ou plusieurs agents actifs (p. ex. un peptide aromatique-cationique). La présente technologie concerne des compositions à base de peptides aromatiques-cationiques liés à des RPBQ, ainsi que des utilisations de ces compositions. Dans certains modes de réalisation, le peptide aromatique-cationique comprend un composé 2',6'-diméthyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2 ou D-Arg-2',6'-Dmt-Lys-Phe-NH2.
PCT/US2015/032689 2014-05-28 2015-05-27 Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations WO2015183963A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003718P 2014-05-28 2014-05-28
US62/003,718 2014-05-28

Publications (2)

Publication Number Publication Date
WO2015183963A2 WO2015183963A2 (fr) 2015-12-03
WO2015183963A3 true WO2015183963A3 (fr) 2016-01-21

Family

ID=54700042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/032689 WO2015183963A2 (fr) 2014-05-28 2015-05-27 Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2015183963A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2968443T3 (pl) 2013-03-15 2022-02-07 Protagonist Therapeutics, Inc. Analogi hepcydyny i ich zastosowania
KR20230036156A (ko) 2014-05-16 2023-03-14 프로타고니스트 테라퓨틱스, 인코포레이티드 α4β7 인테그린 티오에테르 펩티드 길항제
RU2736637C9 (ru) 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника
AU2015328002A1 (en) 2014-10-01 2017-04-27 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3008849A1 (fr) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Derives fluoroalkyle, fluoroalcoxy, phenoxy, heteroaryloxy, alcoxy, et amine 1,4-benzoquinone pour le traitement de troubles du stress oxydatif
CA3009834A1 (fr) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues de mimetiques d'hepcidine a demi-vie in vivo amelioree
WO2018191732A1 (fr) * 2017-04-14 2018-10-18 Bioelectron Technology Corporation Méthodes et compositions pour le traitement d'une inflammation et du stress oxydatif
US10278957B2 (en) * 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP3749345A4 (fr) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. Mimétiques d'hepcidine conjugués
TN2021000075A1 (en) 2018-10-17 2023-01-05 Ptc Therapeutics Inc 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
EP3997105A4 (fr) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
EP4038076A1 (fr) 2019-10-04 2022-08-10 Stealth BioTherapeutics Inc. Analogues chinone, hydrochinone et naphtochinone de vatiquinone pour le traitement de maladies à troubles mitochondriaux
IL294680A (en) 2020-01-15 2022-09-01 Janssen Biotech Inc Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
PE20240631A1 (es) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23
US11786486B2 (en) 2021-07-08 2023-10-17 Ptc Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029796A1 (en) * 2000-07-18 2004-02-12 Hazel Szeto Medicinal uses of mu-opioid receptor agonists
US20100273892A1 (en) * 2009-04-28 2010-10-28 Miller Guy M Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
WO2012170773A1 (fr) * 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Traitement adjuvant au traitement des maladies mitochondriales avec des quinones et des naphtoquinones
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
WO2014039862A1 (fr) * 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Dérivés quinone destinés à être utilisés dans la modulation de l'état d'oxydoréduction chez des individus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029796A1 (en) * 2000-07-18 2004-02-12 Hazel Szeto Medicinal uses of mu-opioid receptor agonists
US20100273892A1 (en) * 2009-04-28 2010-10-28 Miller Guy M Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
WO2012170773A1 (fr) * 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Traitement adjuvant au traitement des maladies mitochondriales avec des quinones et des naphtoquinones
WO2014039862A1 (fr) * 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Dérivés quinone destinés à être utilisés dans la modulation de l'état d'oxydoréduction chez des individus
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHRADER, WD ET AL.: "Alpha-Tocotrienol Quinone Modulates Oxidative Stress Response And The Biochemistry Of Aging.", BIOORG MED CHEM LETT., vol. 21, no. 12, 15 June 2011 (2011-06-15), pages 3693 - 3698, XP002663593, DOI: doi:10.1016/J.BMCL.2011.04.085 *

Also Published As

Publication number Publication date
WO2015183963A2 (fr) 2015-12-03

Similar Documents

Publication Publication Date Title
WO2015183963A3 (fr) Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations
WO2016004093A3 (fr) Compositions thérapeutiques comprenant des inhibiteurs de la galectine-3 et utilisations de celles-ci
WO2015183995A3 (fr) Compositions thérapeutiques comprenant de la frataxine, de la lactoferrine et des enzymes mitochondriales génératrices d'énergie et leurs utilisations
WO2014165607A3 (fr) Formulations peptidiques cationiques aromatiques, compositions et procédés d'utilisation
WO2014205317A3 (fr) Peptides cycliques utilisés en tant qu'agents de ciblage de protéines
WO2017044894A3 (fr) Peptides localisant le cartilage
PH12015502002A1 (en) Tripeptide epoxy ketone protease inhibitors
MX361590B (es) Suministro topico de composiciones para la piel que tienen ph bajo.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
WO2015070224A3 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
MX2019012884A (es) Terapia de combinacion.
WO2017100700A3 (fr) Peptides pour thérapie rénale
CA3010568A1 (fr) Supports nanofibreux oromumuqueux pour traitement therapeutique
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
JO3326B1 (ar) مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد
UA111599C2 (uk) Композиція каспофунгіну
WO2012053013A3 (fr) Compositions pharmaceutiques d'agents anti-acné
EP4342461A3 (fr) Compositions pharmaceutiques et utilisations contre des troubles du stockage lysosomal
MX2022013450A (es) Formulaciones farmaceuticas.
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
WO2016015798A9 (fr) Composition de film orodispersible, comprenant de l'énalapril pour le traitement de l'hypertension dans une population pédiatrique
WO2015183985A3 (fr) Compositions thérapeutiques comprenant des naphthoquinones et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15798679

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09/03/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15798679

Country of ref document: EP

Kind code of ref document: A2